Figure 1 | British Journal of Cancer

Figure 1

From: Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

Figure 1

(A) Representative anatomical magnetic resonance scans of PaCa13 tumours after treatment with vehicle control (0.9% saline), maximum tolerated dose gemcitabine (MTD gem; 240 mg kg−1 on days 1, 8, and 15), or metronomic gemcitabine (30 mg kg−1, q3d) for 4 weeks. (B) Effects of different treatments on PaCa8 and PaCa13 tumour growth. Columns, mean of 4–5 tumours; bars, s.e. *P<0.05, significantly different from that of vehicle control.

Back to article page